US · Healthcare · Medical Devices
EPS came in at 0.31 against a street estimate of 0.23 — a beat of 34.8%.
Analysts rate Bruker Corporation a buy (7 buy, 7 hold, 0 sell out of 14) with an average price target of $59.75.
| Fund | Stake |
|---|---|
| Orbis Allan Gray Ltd | 11.79% |
| FMR Inc | 10.58% |
| BlackRock Inc | 7.34% |
| Pallas Capital Advisors LLC | 6.23% |
| Vanguard Portfolio Management, LLC | 3.19% |
| Vanguard Capital Management, LLC | 3.16% |
| State Street Corp | 2.57% |
| Edmond de Rothschild Holding S.A. | 2.21% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-30 |
| Shareholder vote results · Q2 2026 | 2026-05-21 |
| Company announcement · Q2 2026 | 2026-05-15 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Annual report FY2025 | 2026-02-27 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Reconfirms FY2026 revenue and EPS guidance; expects Q2 organic growth return Bruker Corporation reported Q1 2026 revenues of $823.4 million, up 2.7% year-over-year but down 4.4% organically when excluding acquisitions and favorable currency effects. The company's key | 2026-05-06 |
| FY26 revenue and EPS guidance initiated; expects 4-5% revenue growth Bruker Corporation reported challenging 2025 results but provided encouraging 2026 guidance. In Q4 2025, revenues were $977.2 million (flat year-over-year but down 5% organically), with non- | 2026-02-12 |
| Q4 2025 revenue guidance and 2026 outlook provided at healthcare conference Bruker Corporation announced preliminary Q4 2025 revenue of $965-970 million and provided 2026 guidance during the J.P. Morgan Healthcare Conference on January 12, 2026. Key highlights: The | 2026-01-12 |
| FY2025 guidance lowered; FY2026 cost-savings initiatives progressing Bruker Corporation reported Q3 2025 revenues of $860.5 million, essentially flat year-over-year but down 4.5% organically, reflecting weak demand in academic and research instruments. The co | 2025-11-03 |
| FY2025 revenue guidance lowered; FY2026 cost savings initiative announced Bruker Corporation, a life-science research instruments company, reported disappointing Q2 2025 results with revenues of $797.4 million, essentially flat year-over-year but down 7% organical | 2025-08-04 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bruker Corporation — free to start.
Google PlayApp StoreData updated 2026-08-05.